Difference between revisions of "Low-grade serous ovarian cancer"
Jump to navigation
Jump to search
Warner-admin (talk | contribs) |
m |
||
| Line 18: | Line 18: | ||
|[http://www.ncbi.nlm.nih.gov/pmc/articles/pmc7655017/ Monk et al. 2020 (MILO)] | |[http://www.ncbi.nlm.nih.gov/pmc/articles/pmc7655017/ Monk et al. 2020 (MILO)] | ||
|2013-2016 | |2013-2016 | ||
| − | |style="background-color:#1a9851"|Phase | + | |style="background-color:#1a9851"|Phase 3 (C) |
| − | |Binimetinib | + | |[[#Binimetinib_monotherapy_99|Binimetinib]] |
| − | | style="background-color:#ffffbf" |Did not meet primary endpoint of PFS | + | | style="background-color:#ffffbf" |Did not meet primary endpoint of PFS<br>Median PFS: 10.6 vs 9.1 mo<br>(HR 0.83, 95% CI 0.54-1.27) |
|- | |- | ||
|} | |} | ||
| Line 45: | Line 45: | ||
|[http://www.ncbi.nlm.nih.gov/pmc/articles/pmc7655017/ Monk et al. 2020 (MILO)] | |[http://www.ncbi.nlm.nih.gov/pmc/articles/pmc7655017/ Monk et al. 2020 (MILO)] | ||
|2013-2016 | |2013-2016 | ||
| − | |style="background-color:#1a9851"|Phase | + | |style="background-color:#1a9851"|Phase 3 (C) |
| − | |Binimetinib | + | |[[#Binimetinib_monotherapy_99|Binimetinib]] |
| − | | style="background-color:#ffffbf" |Did not meet primary endpoint of PFS | + | | style="background-color:#ffffbf" |Did not meet primary endpoint of PFS<br>Median PFS: 10.6 vs 9.1 mo<br>(HR 0.83, 95% CI 0.54-1.27) |
|- | |- | ||
|} | |} | ||
| Line 71: | Line 71: | ||
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3627419/ Farley et al. 2013 (GOG-0239)] | |[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3627419/ Farley et al. 2013 (GOG-0239)] | ||
|2007-2009 | |2007-2009 | ||
| − | | style="background-color:#91cf61" |Phase | + | | style="background-color:#91cf61" |Phase 2 |
|- | |- | ||
|} | |} | ||
| Line 96: | Line 96: | ||
|[http://www.ncbi.nlm.nih.gov/pmc/articles/pmc7655017/ Monk et al. 2020 (MILO)] | |[http://www.ncbi.nlm.nih.gov/pmc/articles/pmc7655017/ Monk et al. 2020 (MILO)] | ||
|2013-2016 | |2013-2016 | ||
| − | |style="background-color:#1a9851"|Phase | + | |style="background-color:#1a9851"|Phase 3 (C) |
| − | |Binimetinib | + | |[[#Binimetinib_monotherapy_99|Binimetinib]] |
| − | | style="background-color:#ffffbf" |Did not meet primary endpoint of PFS | + | | style="background-color:#ffffbf" |Did not meet primary endpoint of PFS<br>Median PFS: 10.6 vs 9.1 mo<br>(HR 0.83, 95% CI 0.54-1.27) |
|- | |- | ||
|} | |} | ||
Revision as of 01:12, 8 February 2022
Section editor transclusions Note: this page has regimens which are specific to low-grade serous ovarian cancer (LGSOC). Please see the main ovarian cancer page for other chemotherapy regimens.
Relapsed or recurrent disease
Doxorubicin pegylated liposomal monotherapy
| back to top |
Regimen
| Study | Years of enrollment | Evidence | Comparator | Comparative Efficacy |
|---|---|---|---|---|
| Monk et al. 2020 (MILO) | 2013-2016 | Phase 3 (C) | Binimetinib | Did not meet primary endpoint of PFS Median PFS: 10.6 vs 9.1 mo (HR 0.83, 95% CI 0.54-1.27) |
Chemotherapy
- Pegylated liposomal doxorubicin (Doxil) 40 mg/m2 IV over 60 minutes once on day 1
28-day cycles
References
- MILO: Monk BJ, Grisham RN, Banerjee S, Kalbacher E, Mirza MR, Romero I, Vuylsteke P, Coleman RL, Hilpert F, Oza AM, Westermann A, Oehler MK, Pignata S, Aghajanian C, Colombo N, Drill E, Cibula D, Moore KN, Christy-Bittel J, Del Campo JM, Berger R, Marth C, Sehouli J, O'Malley DM, Churruca C, Boyd AP, Kristensen G, Clamp A, Ray-Coquard I, Vergote I. MILO/ENGOT-ov11: Binimetinib Versus Physician's Choice Chemotherapy in Recurrent or Persistent Low-Grade Serous Carcinomas of the Ovary, Fallopian Tube, or Primary Peritoneum. J Clin Oncol. 2020 Nov 10;38(32):3753-3762. Epub 2020 Aug 21. link to original article contains verified protocol link to PMC article PubMed NCT01849874
Paclitaxel monotherapy
| back to top |
Regimen
| Study | Years of enrollment | Evidence | Comparator | Comparative Efficacy |
|---|---|---|---|---|
| Monk et al. 2020 (MILO) | 2013-2016 | Phase 3 (C) | Binimetinib | Did not meet primary endpoint of PFS Median PFS: 10.6 vs 9.1 mo (HR 0.83, 95% CI 0.54-1.27) |
Note: this trial studied patients with low-grade serous ovarian cancer (LGSOC).
Chemotherapy
- Paclitaxel (Taxol) 80 mg/m2 IV once per day on days 1, 8, 15
28-day cycles
References
- MILO: Monk BJ, Grisham RN, Banerjee S, Kalbacher E, Mirza MR, Romero I, Vuylsteke P, Coleman RL, Hilpert F, Oza AM, Westermann A, Oehler MK, Pignata S, Aghajanian C, Colombo N, Drill E, Cibula D, Moore KN, Christy-Bittel J, Del Campo JM, Berger R, Marth C, Sehouli J, O'Malley DM, Churruca C, Boyd AP, Kristensen G, Clamp A, Ray-Coquard I, Vergote I. MILO/ENGOT-ov11: Binimetinib Versus Physician's Choice Chemotherapy in Recurrent or Persistent Low-Grade Serous Carcinomas of the Ovary, Fallopian Tube, or Primary Peritoneum. J Clin Oncol. 2020 Nov 10;38(32):3753-3762. Epub 2020 Aug 21. link to original article contains verified protocol link to PMC article PubMed NCT01849874
Selumetinib monotherapy
| back to top |
Regimen
| Study | Years of enrollment | Evidence |
|---|---|---|
| Farley et al. 2013 (GOG-0239) | 2007-2009 | Phase 2 |
Targeted therapy
- Selumetinib (Koselugo) 50 mg PO twice per day
28-day cycles
References
- GOG-0239: Farley J, Brady WE, Vathipadiekal V, Lankes HA, Coleman R, Morgan MA, Mannel R, Yamada SD, Mutch D, Rodgers WH, Birrer M, Gershenson DM. Selumetinib in women with recurrent low-grade serous carcinoma of the ovary or peritoneum: an open-label, single-arm, phase 2 study. Lancet Oncol. 2013 Feb;14(2):134-40. Epub 2012 Dec 21. link to original article link to PMC article contains verified protocol PubMed NCT00551070
Topotecan monotherapy
| back to top |
Regimen
| Study | Years of enrollment | Evidence | Comparator | Comparative Efficacy |
|---|---|---|---|---|
| Monk et al. 2020 (MILO) | 2013-2016 | Phase 3 (C) | Binimetinib | Did not meet primary endpoint of PFS Median PFS: 10.6 vs 9.1 mo (HR 0.83, 95% CI 0.54-1.27) |
Chemotherapy
- Topotecan (Hycamtin) 1.25 mg/m2 IV over 30 minutes once per day on days 1 to 5
21-day cycles
References
- MILO: Monk BJ, Grisham RN, Banerjee S, Kalbacher E, Mirza MR, Romero I, Vuylsteke P, Coleman RL, Hilpert F, Oza AM, Westermann A, Oehler MK, Pignata S, Aghajanian C, Colombo N, Drill E, Cibula D, Moore KN, Christy-Bittel J, Del Campo JM, Berger R, Marth C, Sehouli J, O'Malley DM, Churruca C, Boyd AP, Kristensen G, Clamp A, Ray-Coquard I, Vergote I. MILO/ENGOT-ov11: Binimetinib Versus Physician's Choice Chemotherapy in Recurrent or Persistent Low-Grade Serous Carcinomas of the Ovary, Fallopian Tube, or Primary Peritoneum. J Clin Oncol. 2020 Nov 10;38(32):3753-3762. Epub 2020 Aug 21. link to original article contains verified protocol link to PMC article PubMed NCT01849874